Navigation Links
'Twinkle after-effect' can help retinal patients detect vision loss quickly and cheaply
Date:10/26/2007

Boston, MAScientists at Schepens Eye Research Institute, an affiliate of Harvard Medical School, have discovered a simple and inexpensive way for patients with retinal and other eye disease to keep track of changes in their vision loss. In a study published in this weeks PLoS ONE (October 24, 2007) they demonstrate that a compelling visual illusion known as the induced twinkle after-effect (TAE) can accurately identify the location and breadth of actual blind spots in people with retinal disease. The twinkle after-effect is a twinkling that people can see in a blind spot when they stare at a blank screen after staring at a noisy visual target such as a detuned television screen.

Our hope is that we can make this simple technique available online or on a DVD, says Dr. Peter Bex, associate scientist at Schepens Eye Research Institute and the principal investigator of the study. This will be particularly helpful with patients who have glaucoma, diabetic retinopathy or macular degeneration where early detection of changes in vision can impact the effectiveness of treatments.

According to Bex, many people fail to seek help when they develop blind spots in their vision, because their brains automatically compensate or fill in the missing information in their visual field. Since everyone has a blind spot where the optic nerve meets the retina, this perceptual fill in process is useful for normally sighted people, allowing them a complete visual image. But this innate process can mask the effects of serious disorders such as diabetic retinopathy and glaucoma and keep sufferers from seeking help until the vision loss is very serious or they bump into objects they can no longer see.

The traditional gold standard method for detecting blind spots (scotomas) is very expensive and time consuming and must be done in an ophthalmologists office. The technique known as retinal specific microperimetry is a diagnostic tool that costs nearly 50 thousand
'/>"/>

Contact: Patti Jacobs
pjacobs12@comcast.net
617-868-0077
Public Library of Science
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
2. Six previously blind patients detect light, motion, identify objects with retinal prostheses
3. Retinal scans eyed for New Mexico show cattle
4. New gene reduces retinal degeneration in fruit flies
5. Prosthetic retinal cells let blind mice see light
6. Transplanted photoreceptor precursor cells restore visual function in mice with retinal degeneration
7. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
8. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
9. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
10. Potential Cure for Lymphoma in HIV patients
11. Implanted Devices Detect High-Risk Heart Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/98rrmr/biometrics_for ... "Biometrics for Banking; Market & Technology Analysis, Adoption ... offering. The adoption for banking purposes ... the forecast is that by 2020 it will ... in delivering biometric systems to the banking industry. ...
(Date:7/8/2015)... , N.J. and NEW YORK , ... and Guidepoint today announced BD & ... healthcare companies with free access to Guidepoint,s expert network ... start-ups that are developing cutting-edge technologies to improve healthcare ... dedicated Guidepoint research manager, each start-up entrepreneur will be ...
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... infectious disease today. It is estimated that two billion ... active symptoms. Nine million new cases of active disease ... is predominantly a lung disease. It is caused by ... but it is still not clear how exactly this ...
... dwelling in ocean-bottom sediments appears in laboratory tests ... myeloma cells, and potentially with less toxicity than ... the November issue of Cancer Cell. , The ... or inhibit cancer cells' proteasomes from working effectively. ...
... you eat and when, your nervous system must coordinate ... about energy level, food preferences, and metabolic need, while ... food, determined by its smell and taste. , Scientists ... olfactory signals beginning with chemical receptors in the mouth, ...
Cached Biology News:How does Mycobacterium tuberculosis infect the lung? 2Compound from marine bacteria shows potential as multiple myeloma therapy 2Compound from marine bacteria shows potential as multiple myeloma therapy 3How Fruitflies Know It's Time for Lunch 2How Fruitflies Know It's Time for Lunch 3
(Date:7/29/2015)... VANCOUVER , July 29, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company, is pleased to announce ... dermal injector (RCI-02) have been locked.  Prototypes for ... to prepare for an application for CE mark ... Europe in 2016. (Photo: ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi LifeSciences™ formalized ... specializing in Clinical Trial Management. CSSi LifeSciences is specialized in strategic, marketing, and ... PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, and Clinical ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... (BI) advanced cell culture products, announces the availability of BI’s line of human ... Biological Industries, these stem cell differentiation media offer a complete system for multipotency ...
(Date:7/28/2015)... A n ... rapidly developing and commercialising innovative medicines to transform patient quality ... Highly experienced management team; blue chip ... Mereo BioPharma Group Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, ... £76.5m), gross, from blue chip institutional investors and simultaneously acquired ...
Breaking Biology Technology:RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11
... Reportlinker.com announces that a new market research report ... Biomarkers - technologies,markets and companies ... This report follows the broad definition of a ... and evaluated as an indicator of normal biological or ...
... Operating Results ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... Repositioning Collaboration With Pfizer -- CHARLOTTESVILLE, Virginia, November 9, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology Technology:Reportlinker Adds Biomarkers - Technologies, Markets And Companies 2Reportlinker Adds Biomarkers - Technologies, Markets And Companies 3Reportlinker Adds Biomarkers - Technologies, Markets And Companies 4Reportlinker Adds Biomarkers - Technologies, Markets And Companies 5Reportlinker Adds Biomarkers - Technologies, Markets And Companies 6Reportlinker Adds Biomarkers - Technologies, Markets And Companies 7Reportlinker Adds Biomarkers - Technologies, Markets And Companies 8Reportlinker Adds Biomarkers - Technologies, Markets And Companies 9Reportlinker Adds Biomarkers - Technologies, Markets And Companies 10Reportlinker Adds Biomarkers - Technologies, Markets And Companies 11Reportlinker Adds Biomarkers - Technologies, Markets And Companies 12Reportlinker Adds Biomarkers - Technologies, Markets And Companies 13Reportlinker Adds Biomarkers - Technologies, Markets And Companies 14Reportlinker Adds Biomarkers - Technologies, Markets And Companies 15Reportlinker Adds Biomarkers - Technologies, Markets And Companies 16Reportlinker Adds Biomarkers - Technologies, Markets And Companies 17Reportlinker Adds Biomarkers - Technologies, Markets And Companies 18Reportlinker Adds Biomarkers - Technologies, Markets And Companies 19Reportlinker Adds Biomarkers - Technologies, Markets And Companies 20Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results 2Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results 3Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results 4Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results 5Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results 6Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results 7Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results 8Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results 9Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results 10Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results 11Biovista Announces a Drug Repositioning Collaboration With Pfizer 2Biovista Announces a Drug Repositioning Collaboration With Pfizer 3Biovista Announces a Drug Repositioning Collaboration With Pfizer 4Biovista Announces a Drug Repositioning Collaboration With Pfizer 5Biovista Announces a Drug Repositioning Collaboration With Pfizer 6Biovista Announces a Drug Repositioning Collaboration With Pfizer 7